Skip to main content

EDITORIAL article

Front. Psychiatry

Sec. Schizophrenia

Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1591274

This article is part of the Research Topic Neuroimaging in Psychiatry 2023: Schizophrenia View all 9 articles

Editorial: Neuroimaging in Psychiatry 2023: Schizophrenia

Provisionally accepted
  • 1 University of Cagliari, Cagliari, Italy
  • 2 Neurochemical Research Unit, Department of Psychiatry University of Alberta, Edmonton, Canada, Edmonton, Alberta, Canada

The final, formatted version of the article will be published soon.

    Schizophrenia is a complex mental disorder that affects about 1% of the World's population (1). Despite extensive research, the neurobiological mechanisms underlying schizophrenia remain incompletely understood (1,2). It is clear that schizophrenia remains one of the most complex and distressing psychiatric disorders, with a clinical picture characterized by a series of positive symptoms (hallucinations, delusions) (3), negative symptoms (diminished affect, social withdrawal) and cognitive impairments (4)(5)(6). Alongside the most significant advances in neurobiological research, it is evident that voxel-based morphometry and high-resolution diffusion imaging reveal widespread reductions in gray matter volume (GMV) and white matter integrity (7)(8)(9). It is recognized that structural deficits, predominantly in the prefrontal cortex, temporal lobes and striatum, are often correlated with disease severity and cognitive decline; in particular, early-onset schizophrenia presents more pronounced structural abnormalities, offering unique insights into its pathophysiological mechanisms (10). Functional imaging studies show reduced activation in the anterior insula and anterior cingulate cortex during socio-cognitive tasks, suggesting a disturbed integration of emotional and cognitive processes; these results are in line with behavioral observations of compromised social functioning, emphasizing the need for targeted and tailored therapeutic interventions with a view to precision medicine (11)(12)(13). Machine learning approaches have perfected the prediction of treatment outcomes in schizophrenia (3). Multimodal imaging biomarkers, incorporating structural and functional data, demonstrate high accuracy in identifying treatment-resistant schizophrenia (TRS) and in predicting disease trajectories (14,15). Individualized network parcellation and advanced classification algorithms achieve robust performance, with predictive accuracies exceeding 90% in some studies; moving forward in this direction, an increasingly exploratory literature on the integration of neuroimaging, computational models, and large-scale data repositories suggests a new era in schizophrenia research (16,17). Transdiagnostic frameworks that transcend traditional diagnostic boundaries are set to improve our understanding of common and distinct pathophysiological features, facilitating the differential diagnosis with bipolar disorder, and ultimately reducing the stigma associated with the disease and paving the way for integrated management of these clinical aspects (18)(19)(20), with a view to increasingly multidisciplinary rehabilitation through the use of virtual reality techniques, stimulation of mirror neurons, obtaining better outcomes with a reduction in the invasiveness of treatments (21)(22)(23). Recent advances in neuroimaging techniques may provide new insights and allow for highly specialized information on the neural correlates of schizophrenia (5,24). In this perspective, this research topic aims to highlight the latest discoveries in the field of neuroimaging and explore their potential implications for the diagnosis and treatment of schizophrenia, while providing a valuable resource for healthcare professionals, both from a clinical and an etiopathogenetic point of view (25).Regarding the analysis of the neurobiological heterogeneity of the clinical state at high risk of psychosis, Oliver et al. present a study based on a large neuroimaging dataset of individuals with clinical high-risk for psychosis (CHR-P) who meet the brief limited intermittent psychotic symptoms (BLIPS) criteria obtained by combining data from four independently conducted studies. The authors found weak or moderate evidence of no differences in global gray matter (GM), regional cerebral blood flow (rCBF), hippocampal and striatal attenuation psychotic symptoms (APS) and BLIPS, suggesting based on their results that rCBF alone may not be suitable for risk stratification in CHR-P subjects. In their study on the differentiation of the trajectories of retinal morphology aging in schizophrenia and their associations with cognitive dysfunctions, Domagała et al. demonstrate that, in patients suffering from schizophrenia, the retinal macula undergoes accelerated atrophy starting from the third decade of life, similarly to the dynamics of white matter changes analyzed in relation to the hypothesis of accelerated aging. The curves indicating age-related changes in other retinal structures were generally very similar in both groups, only with more pronounced thinning in the patient samples, with associations between the macula, ganglion cell complex and the age of the patients only concerned the middle-aged subgroup, hypothesizing on the basis of the data presented that retinal abnormalities in schizophrenia do not increase linearly over the course of life. Additionally, Mamah et al. in an analysis based on white matter tracts in schizophrenia, bipolar disorder, aging and dementia using high spatial and directional resolution image diffusion, provide preliminary data comparing image diffusion metrics between younger psychiatric populations and older cohorts using an automated trait-based analysis. The study shows that white matter tract volumes did not differ significantly between the groups evaluated, while there were significant differences in fractional anisotropy of the tracts in the various tracts studied. The authors, using an automated tractography tool, the study showed white matter integrity significantly compromised with aging, suggesting demyelination. Shifting the focus to empathy in schizophrenia, Knobloch et al. analyze in their study the neural alterations during emotion recognition and affective sharing. From a behavioral point of view, the patients only showed a prolonged response time in the age discrimination tests, while for the emotion processing tests, the patients showed a difference in neural response, without an observable behavioral correlate. The study suggests that the patients have deficits in processing complex visual information regardless of the emotional content at a behavioral level, and that these deficits coincide with aberrant neural activation patterns in the emotion processing networks. Furthermore, in their systematic review Merola et al. examines transdiagnostic markers in the psychosis continuum, highlighting results that provide preliminary evidence of potential transdiagnostic alterations in brain activity in specific regions associated with psychosis, although they are not confirmed by survival to correction for multiple comparisons. In an in-depth study on the illness-related variables and abnormalities of resting-state brain activity in schizophrenia, Giuliani et al. emphasize how attention/vigilance deficits were negatively associated with the dorsal resting-state (RS) activity of the anterior cingulate and, together with depression, were positively associated with the RS activity of the right dorsolateral prefrontal cortex. These deficits and the impairment of reasoning/problem solving, together with conceptual disorganization, were associated with RS activity of the right inferior parietal lobe and right parietal temporal junction, while highlighting how neurocognitive deficits and negative symptoms are associated with different neural markers.Delving into brain structure, Zhang et al. present a study describing how individualized multimodal biomarkers obtained from magnetic resonance imaging predict the one-year clinical outcome in the first episode of patients with schizophrenia not treated with drugs; the study evaluated the structural morphology and functional topological characteristics related to treatment response using an individualized parcellation analysis in combination with machine learning (ML). This allowed us to highlight the potential of individual-specific network parcellation in the prediction of treatment-resistant schizophrenia, emphasizing the crucial role of feature attributes in the accuracy of the predictive model Finally, Wang et al. provide a meta-analysis of structural and functional brain abnormalities in early-onset schizophrenia; their work revealed that certain regions in the EOS showed significant structural or functional abnormalities, such as the temporal gyri, prefrontal cortex and striatum. These results may help to deepen our understanding of the pathophysiological (26) mechanisms underlying EOS and provide potential biomarkers for the diagnosis or treatment of EOS.In conclusion, although the progress of neuroimaging is extremely promising, challenges remain, including the need for larger and more diverse data sets and ethical considerations regarding data privacy (27). Despite these limitations, the integration of neuroimaging with computational methods continues to shape the future of schizophrenia research, fostering a deeper understanding of this enigmatic disorder (28). A combined approach based on neuroimaging, the latest machine learning techniques and evidence from improvements in the final outcome of the most modern rehabilitative integrations with the most traditional methods, is leading us towards emerging transdiagnostic frameworks, challenging traditional diagnostic boundaries and supporting a continuum-based approach to psychosis (29). Neuroimaging studies reveal pathophysiological characteristics common to all disorders, such as interrupted connectivity and abnormalities in neurological development (30). These insights pave the way for integrative models that take into account genetic, environmental and developmental factors, filling in the gaps in our understanding and ultimately enabling us to achieve results that pave the way for future innovations in the research and treatment of psychosis.

    Keywords: Neuroimaging, biomarkers, Neurobiology, Schizophrenia, psychosis, machine learning

    Received: 10 Mar 2025; Accepted: 31 Mar 2025.

    Copyright: © 2025 Tusconi and Dursun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Massimo Tusconi, University of Cagliari, Cagliari, Italy
    Serdar M Dursun, Neurochemical Research Unit, Department of Psychiatry University of Alberta, Edmonton, Canada, Edmonton, Alberta, Canada

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more